19 Jul ImmPACT Bio
Sumant Ramachandra, M.D., Ph.D., CEO
Oct. 11 | 3:15pm | Rentschler ATMP Ballroom
West Hills, CA
(Private)
ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies for patients with cancer or autoimmune disease. The company’s logic-gate-based CAR T-cell platforms, licensed from University of California, Los Angeles (UCLA) Technology Development Group, address key biological challenges in treating cancer. ImmPACT Bio’s technologies are specifically designed to prevent antigen escape, and to overcome the immunosuppressive tumor microenvironment. The Company’s technology is based on the work of pioneering scientists Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from UCLA. In addition, another logic-gate-based CAR T-cell technology is based on the work of Gideon Gross, Ph.D., from the MIGAL-Galilee Research Institute, to address the prevention of ‘on-target – off-tumor’ toxicities.
